NCIC CLINICAL TRIALS GROUP – GI DISEASE SITE COMMITTEE

NEUROENDOCRINE
DISEASE ORIENTED GROUP

AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO

DATE SATURDAY, MAY 3rd, 2014

TIME: 15:00 – 15:30

CHAIRS: DR. TIM ASMIS & DR. HAGEN KENNECKE

15:00 WELCOME AND INTRODUCTION
DR. H. KENNECKE AND DR. T. ASMIS

15:05 – 15:10 COMPLETED TRIALS

**NEC.2 (CALGB 80701):** RANDOMIZED PHASE II STUDY OF EVEROLIMUS ALONE VERSUS EVEROLIMUS PLUS BEVACIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC NEUROENDOCRINE TUMORS

DR. H. KENNECKE

15:10 – 15:25 ACTIVE TRIALS

**NEC.3 (ALLIANCE 021202):** PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS

DR. T. ASMIS

15:25 – 15:30 INTERGROUP TASK FORCE UPDATE
DR. T. ASMIS

15:30 CLOSING REMARKS